https://bioinformant.com/ips-cell-clinical-trials/
iPSC Clinical Trials Involving Cellular Therapeutics
The first clinical trial using iPSCs for any purpose occurred in 2008. Today in 2021, the total number of iPSC clinical trials has risen to 54. Of these 54 trials, a select few are now administering iPSC-derived cell therapeutics to human patients.
These cell therapy trials include:
CYP-001, an iPSC-derived MSC product by Cynata Therapeutics
CYP-004, also an iPSC-derived MSC product by Cynata Therapeutics
FT500, an iPSC-derived NK cell product by Fate Therapeutics
In 2016, Cynata Therapeutics received approval to launch the world’s first formal trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD.
CYNATA - 2021 The Year of Multiple Trials, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.5¢ | 27.5¢ | $29.94K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 10159 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |